Search results for " Mental health"

showing 10 items of 3677 documents

Eine vergleichende Untersuchung zum Reizdarmsyndrom bei konsekutiven Patienten zweier internistischer Ambulanzen

2001

OBJECTIVES We investigated the nature of illness behavior and the meaning of emotional deficiencies during childhood in patients with irritable bowel diseases (IBS). DATA A consecutive study in two tertiary referral centers was conducted with 48 patients suffering from irritable bowel diseases (IBS) and 91 patients with inflammatory bowel disease (IBD). METHODS The diagnosis of IBS was made by following the Manning criteria, a positive diagnosis of IBD was established through physical, endoscopic and radiologic examinations and was confirmed histologically. Psychological data were obtained by structured psychiatric interviews and psychological self-report measures (GBB). RESULTS We found th…

medicine.medical_specialtyPediatricsReferralbusiness.industryDiseasemedicine.diseaseInflammatory bowel diseasePhysician visitPsychiatry and Mental healthClinical PsychologyEpidemiologyMedicineDoctor–patient relationshipbusinessManning criteriaApplied PsychologyIllness behaviorPPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
researchProduct

The course of psychiatric co-morbidity in patients with breast cancer - results from the prospective multi-centre BRENDA II study

2015

Purpose This study examined the frequency of psychiatric co-morbidity in patients with breast cancer, its changes over time and predictors for these changes. Methods In a prospective study with measurements before surgery (t1, baseline), 1 month (t2) and 8 months thereafter (t3) using the Patient Health Questionnaire, we examined the course of psychiatric co-morbidity in breast cancer patients. The co-morbidity courses were grouped into healthy (no co-morbidity during the study), acute (co-morbidity at t1 and/or t2, but not at t3), emerging (no co-morbidity at t1, but at t3) and chronic (co-morbidity at t1 and t3). Results Of the 598 participants, 19% had acute, 10% emerging and 9% chronic …

medicine.medical_specialtyPediatricsbusiness.industry05 social sciencesCancerExperimental and Cognitive PsychologyOdds ratio050108 psychoanalysismedicine.diseaseComorbidityConfidence intervalPatient Health Questionnaire03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineBreast cancerOncologyQuality of life030220 oncology & carcinogenesismental disordersmedicine0501 psychology and cognitive sciencesPsychiatrybusinessProspective cohort studyPsycho-Oncology
researchProduct

I06 Dysphagia In Huntington`s Disease: A Multicenter Study

2014

Background Dysphagia is a common complication of neurogenerative disorders, and a leading cause of death due to aspiration pneumonia. Little is known about the frequency and the characteristics of dysphagia in HD. Well-balanced strategies for treatment and prevention of dysphagia in HD are lacking. Objetives To determine the prevalence of dysphagia in HD. Methods National, multicenter, observational, cross-sectional Study (Spanish EHDN). Dysphagia was assessed using the questionnaire EAT-10 (eating assessment tool), caregiver burden using the SumaCare, functional capacity using the TFC score, disease severity using the Unified HD Rating Scale (UHDRS), psyquiatric status (PBA-s), nutritional…

medicine.medical_specialtyPediatricsbusiness.industryCaregiver burdenAspiration pneumoniamedicine.diseaseDysphagiaPsychiatry and Mental healthHuntington's diseaseQuality of lifeotorhinolaryngologic diseasesNursing Interventions ClassificationPhysical therapyMedicineSurgeryNeurology (clinical)medicine.symptombusinessBody mass indexCause of deathJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Psycho-oncological care in certified cancer centres-a nationwide analysis in Germany

2012

Background Over the last few years, a nationwide voluntary certification system for cancer centres has been established in Germany. To qualify for certification, cancer centres must provide psycho-oncological care to every patient who needs it. The aim of this study was to find out how many patients have been treated by a psycho-oncologist in the certified centres. Methods All cancer centres in Germany that were re-certified in 2010 provided data documenting how many patients with primary cancer received at least 30 min of psycho-oncological consultation in 2009. Results Data from n = 456 certified cancer centres were available. In the centres, a total of 36 165 patients were seen by a psyc…

medicine.medical_specialtyPediatricsbusiness.industryColorectal cancereducationMEDLINECancerExperimental and Cognitive PsychologyCertificationmedicine.diseasehumanitiesPsychiatry and Mental healthProstate cancerBreast cancerOncologyFamily medicineHealth caremedicinebusinessLung cancerPsycho-Oncology
researchProduct

W05-01 - Rationale and Design of an RCT Comparing “EMC-Strategy” with TAU in Patients with Major Depression - the EMC Trial

2010

IntroductionFor Major Depression, current guidelines recommend treatment durations of 3-8 weeks until optimisation in case of insufficient outcome. Many retrospective studies indicate that improvement (HAMD-17 decrease ≥20%) occurs usually within 10-14 days and that non-improvement after 14 days of treatment is highly predictive for poor clinical outcome.MethodsIn level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to “early medication change” (EMC) strategy or treatment according to current guidelines (TAU). EMC schedules treatment optimisations on day 15 and day 29 in case of non-improvement. TAU schedules a medication change after 28 days …

medicine.medical_specialtyPediatricsbusiness.industryRetrospective cohort studylaw.inventionMedication changeClinical PracticePsychiatry and Mental healthRandomized controlled triallawMedicineIn patientbusinessPsychiatryDepression (differential diagnoses)European Psychiatry
researchProduct

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hy…

2014

Introduction GXR, a selective α2A-adrenergic agonist, is a non-stimulant ADHD treatment approved in the USA for children and adolescents, and in Canada for children. Objectives To evaluate long-term maintenance of efficacy of GXR in children and adolescents with ADHD who respond to an initial open-label, short-term trial. Aims To determine if there is a higher rate of treatment failure for placebo vs GXR during the double-blind randomised-withdrawal phase (RWP) (NCT01081145). Methods Patients (6–17 years) meeting DSM-IV-TR criteria for ADHD, baseline ADHD Rating Scale-IV (ADHD-RS-IV) ≥32 and Clinical Global Impressions-Severity (CGI-S) ratings ≥4 were enrolled. Following 7-week dose optimiz…

medicine.medical_specialtyPediatricsbusiness.industryVital signsLong term maintenancemedicine.diseasePlaceboDouble blindPsychiatry and Mental healthmental disordersPhysical therapymedicineClinical endpointAttention deficit hyperactivity disorderGuanfacine HydrochlorideAdverse effectbusinessEuropean Psychiatry
researchProduct

Gruppentherapeutische Frühintervention für Patienten im Frühstadium der Alzheimererkrankung und deren Angehörige - Eine Pilotstudie

2008

Subject Pilot study on an early-interventional group therapy for patients with incipient Alzheimer disease and their relatives. The present study investigates whether scientific progress in terms of earlier time of diagnostic certainty can be used for psychoeducation, maintenance of positive activities and prevention of comorbid depressive episodes. Methods 12 patients (66.8 +/- 5.8 years, MMSE 24.0 +/- 4.0) together with 12 relatives have been treated with a bi-weekly group therapy program. Results For the patients treatment resulted in reduced anxiety, anergia and withdrawal, for their relatives reduced sleep disturbances, irascibility, and aggressiveness have been found. Only one of the …

medicine.medical_specialtyPediatricsbusiness.industrymedicine.medical_treatmentmedicine.diseaseComorbidityGroup psychotherapyPsychiatry and Mental healthClinical PsychologyQuality of lifemedicinePsychoeducationAnxietymedicine.symptomAlzheimer's diseasePsychiatrybusinessProspective cohort studyPsychosocialApplied PsychologyPPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner

2004

The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) re…

medicine.medical_specialtyPharmacologyKidney5-HT3 receptorCell LineMembrane PotentialsMiceNeuroblastomaCellular and Molecular NeuroscienceDopamineCell Line TumorInternal medicinemedicineAnimalsHumansCalcium SignalingReceptorMolecular BiologyDose-Response Relationship DrugbiologyBrain NeoplasmsChemistryFlupentixolPsychiatry and Mental healthEndocrinologyDopamine receptorCompetitive antagonistbiology.proteinLigand-gated ion channelCalciumSerotoninReceptors Serotonin 5-HT3Ion Channel GatingAntipsychotic AgentsSignal Transductionmedicine.drugMolecular Psychiatry
researchProduct

Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis.

2017

Objective: Deficiency of acetyl-l-carnitine (ALC) seems to play a role in the risk of developing depression, indicating a dysregulation of fatty acid transport across the inner membrane of mitochondria. However, data about ALC supplementation in humans are limited. We thus conducted a systematic review and meta-analysis investigating the effect of ALC on depressive symptoms across randomized controlled trials (RCTs). Methods: A literature search in major databases, without language restriction, was undertaken from inception until 30 December 2016. Eligible studies were RCTs of ALC alone or in combination with antidepressant medications, with a control group taking placebo/no intervention or…

medicine.medical_specialtyPlacebonot knownlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicineHumansAdverse effectApplied PsychologyDepression (differential diagnoses)Randomized Controlled Trials as Topicbusiness.industryDepressionIncidence (epidemiology)Confidence intervalAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisDietary SupplementsVitamin B ComplexAntidepressantbusinessAcetylcarnitine030217 neurology & neurosurgeryPsychosomatic medicine
researchProduct